View Item 

Show simple item record

Pelvic irradiation for stage II ovarian carcinoma

dc.contributor.authorTerada, Keith Y.en_US
dc.contributor.authorMorley, George W.en_US
dc.contributor.authorRoberts, James A.en_US
dc.date.accessioned2006-04-07T20:26:16Z
dc.date.available2006-04-07T20:26:16Z
dc.date.issued1988-01en_US
dc.identifier.citationTerada, Keith Y., Morley, George W., Roberts, James A. (1988/01)."Pelvic irradiation for stage II ovarian carcinoma." Gynecologic Oncology 29(1): 26-31. <http://hdl.handle.net/2027.42/27444>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6WG6-4C5GY33-BR/2/10e17494d088c5217f1b396ca45cbbe9en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/27444
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3338660&dopt=citationen_US
dc.description.abstractOver a 20-year period, 34 patients with FIGO stage II ovarian carcinoma were treated with postoperative pelvic irradiation at the University of Michigan. Complications of radiation treatment were minimal. The overall actuarial disease-free 5-year survival was 53%. This was not significantly different for substages IIA, IIB, or IIC. Patients with well-differentiated tumors had a significantly better survival than patients with moderate or poorly differentiated tumors (P &lt; 0.05). The implications for managing stage II ovarian carcinoma are discussed.en_US
dc.format.extent385955 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titlePelvic irradiation for stage II ovarian carcinomaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelOphthalmologyen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelObstetrics and Gynecologyen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Obstetrics and Gynecology, University of Michigan School of Medicine, Ann Arbor, Michigan 48105, U.S.A.en_US
dc.contributor.affiliationumDepartment of Obstetrics and Gynecology, University of Michigan School of Medicine, Ann Arbor, Michigan 48105, U.S.A.en_US
dc.contributor.affiliationumDepartment of Obstetrics and Gynecology, University of Michigan School of Medicine, Ann Arbor, Michigan 48105, U.S.A.en_US
dc.identifier.pmid3338660en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/27444/1/0000484.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0090-8258(88)90142-4en_US
dc.identifier.sourceGynecologic Oncologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0000484.pdf
Size:
376.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.